San Francisco Partner Judith Waltz was quoted in an article titled “Sunshine Act Compliance Stymies Healthcare Firms” in the July 2013 issue of Compliance Week. The article discusses the impact the Sunshine Act will have on drug companies and medical equipment companies. Ms. Waltz was quoted saying, “This may relate to concerns about how their participation will be viewed by patients, or to the increasing prevalence of institutional policies that limit or even preclude involvement in any activity that might be viewed as a conflict of interest for clinical decision making. [If this trend continues,] it could result in some significant constrictions on future research and clinical discussion of existing drugs.”
People
Related News
May 20, 2026
In the News
Scott Johnson Interviewed on Expanded DPA Use to Support Domestic Energy Supply Chains
Foley & Lardner LLP of counsel Scott Johnson appeared on Federal News Network to discuss presidential determinations under the Defense Production Act (DPA).
May 18, 2026
In the News
Judith Waltz Assesses CMS Moratoria and Enforcement Impact
Foley & Lardner LLP Judith Waltz analyzed the impact of new recent federal enforcement actions on home health agencies (HHAs) and hospices in the Report on Medicare Compliance article, “Site Visits Surge for Home Health, Hospice Providers; CMS Implements Enrollment Moratoria.”
May 15, 2026
In the News
Scott Ellis on New SEC Reporting Plan and Implications for the Energy Sector
Foley & Lardner LLP partner Scott Ellis spoke to Law360 for the article, “New SEC Reporting Plan May Not Sway Energy Cos.,” discussing the U.S. Securities and Exchange Commission’s proposed shift from a quarterly to a semiannual earnings reporting schedule for public companies.